| Antivirals Inc. | |||
| Ticker: | AVII | One SW Columbia, Suite 1105 | |
| Exchange: | NASDAQ-National Market | Portland, OR 97201 | |
| Industry: | Manufacturing (SIC Code 2834) | (503) 227-0554 | |
| Type of Shares: | Common Shares | Filing Date: | 1/28/97 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 6/3/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $9.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.63 | |
| Offering Amount: | $18,000,000 | Selling: | $0.36 | |
| Expenses: | - | Reallowance: | $0.10 | |
| Shares Out After: | 10,279,763 |
| Manager | Tier | Phone |
| Paulson Investment Company, Inc. | Lead Manager | (503) 243-6028 |
| Issuer's Law Firm: | Ater Wynne Hewitt Dodson & Skerritt |
| Auditor: | Arthur Andersen |
| Registrar/Transfer Agent: | ChaseMellon Shareholder Services, L.L.C. |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 9/30/96 | 9/30/95 | 9/30/96 | ||
| Revenue: | $0.08 | $0.02 | $0.08 | Assets: | $4.79 |
| Net Income: | -$2.56 | -$1.41 | -$1.94 | Curr Assets: | |
| EPS: | -$0.37 | -$0.18 | -$0.28 | Liabilities: | $3.32 |
| Prior EPS: | -$0.33 | -$1.17 | -$1.34 | Curr Liabilities: | |
| Cash Flow/Oper: | -$1.78 | Equity: | $1.47 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a pioneer company in the field of gene-inactivating technology referred to as antisense and has developed a patented class of antisense compounds which may be useful in the treatment of a wide range of human diseases. The company also has developed new drug delivery technology which may be useful with many FDA-approved drugs as well as with its antisense compounds. The company's long-term product development program combines its NEU-GENE and CYTOPORTER technologies to produce combination drugs with potentional applications for many human diseases. The company has 19 issued patients and several patent applications covering the basic compositions of matter, methods of synthesis, and medical uses of NEU-GENE and CYTOPORTER compounds. Antisense technology has the potential to provide safe and effective treatment for a broad range of diseases. The company's new approach uses synthetic compounds designed to inactivate selected genetic sequences that underlie the disease process and thereby halt the disease. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, working capital and for general corporate purposes. |
| # of Units: | 2,000,000 | |||
| Unit Ticker: | - | Unit Price: | $9.00 | |
| Warrant Ticker: | AVIIW | Warrant Price: | ||
| Warrant Exercise Date: | Warrant Exercise Price: | |||
| Warrant Expiration Date: | ||||
| Warrant Detachable: | Yes | Warrant Detach Date: | ||
| Warrant Callable: | No |
| Unit Composition: 1 Common Share + 1 Warrant |
| Warrant Entitlement: 1 Common Share |